The HIV envelope (Env) glycoprotein is the functional viral protein that is found on the surface of infected cells as well as virions. The envelope protein has been a focal point in the investigation of HIV vaccines due to its susceptibility to neutralizing antibodies (Abs), resulting in extensive research efforts. Monoclonal antibodies (mAbs) have exhibited significant efficacy over the last two decades in the treatment of various diseases, with a primary focus on cancers and immune disorders. Many potent monoclonal antibodies have shown promising results against different types of viral infections. Various immunotherapeutic approaches have been employed in the treatment of NHLs (non-Hodgkin lymphoma), including the use of therapeutic antibodies such as Brentuximab vedotin (Adcetris), Ibritumomab tiuxetan (Zevalin), and rituximab (Rituxan), which have demonstrated encouraging outcomes. HIV-1 infection treatment and prevention have been transformed by combination anti-retroviral therapy (ART). In this study, we examine various mAbs, evaluating their antiviral efficacy in vitro and in vivo. Additionally, this chapter explores the mechanisms employed by HIV-1 to evade these antibodies and proposes potential strategies for the development of enhanced monoclonal antibody-based therapeutics for HIV-1. Future research involves producing vaccine immunogens that stimulate broadly neutralizing antibodies, exploring passive immunization using effective mAbs, integrating mAbs with antiretroviral medications for improved treatment, establishing effective mAbs for sustained protection, and examining their role in HIV treatment research. To optimize their efficacy, protection, and accessibility in an HIV vaccine, more clinical studies and research are needed.